ציין מניה או מטבע קריפטוגרפי בשורת החיפוש כדי לקבל סיכום
PCI Biotech Holding ASA
PCIBPCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. In addition, the company develops fimaVACC for immunotherapy indications, which is in pre-clinical study; fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study for bioprocessing and dermatology indications; and technology for viral vector manufacturing and pre-clinical research for intratumoural immunotherapy. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway. Address: UllernchaussEen 64, Oslo, Norway, 0379
Analytics
מחיר יעד של וול סטריט
264 NOKיחס רווח למחיר
–תשואת דיבידנד
–השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
דמויות מפתח PCIB
ניתוח דיבידנדים PCIB
גידול דיבידנד במשך 5 שנים
–צמיחה מתמשכת
–יחס תשלום ממוצע של 5 שנים
–היסטוריית דיבידנדים PCIB
שווי מניות PCIB
פיננסיים PCIB
תוצאות | 2019 | דינמיקה |